argenx SE ARGX

ARGX Company Overview

argenx SE is a global immunology-focused biotechnology company dedicated to developing antibody-based therapies for the treatment of severe autoimmune diseases and certain cancers. The company operates primarily within the biopharmaceutical and biotechnology industries, with a core emphasis on translating immunology research into targeted, first-in-class medicines. Its business is centered on the discovery, development, and commercialization of proprietary antibody therapeutics designed to selectively modulate the immune system.

The company’s primary revenue driver is its lead product Vyvgart (efgartigimod), an FcRn antagonist approved for the treatment of generalized myasthenia gravis and additional indications, generating the majority of commercial revenue. argenx serves specialist physicians, hospitals, and patients in neurology and immunology markets, particularly those addressing rare and severe autoimmune conditions. Founded in 2008 and originally spun out of academic antibody research, argenx has evolved from a clinical-stage biotechnology firm into a fully integrated commercial organization with global operations and multiple late-stage development programs.